• Radiocleavable Nanoactivators Induce Ferroptosis in Pancreat

  2026-04-30

  Gupta et al. (2025) present a radiocleavable, folate receptor-targeted rare-earth nanoparticle system that delivers controlled intracellular release and induces ferroptosis in pancreatic cancer models. This strategy not only damages mitochondria and enhances ROS-mediated cell death, but also remodels the tumor immune microenvironment, offering a potential path to improved therapeutic efficacy.

• Estradiol (17β-Estradiol): Deep Mechanisms and Research Prot

  2026-04-30

  Explore the advanced molecular mechanisms of estradiol (17 beta-estradiol) in estrogen receptor signaling, with expert guidance on experimental design and unique insights into autophagy and organ protection. This article provides researchers with protocol-level recommendations and new perspectives beyond existing literature.

• Reimagining Cre Recombinase mRNA: Mechanisms and Next-Gen De

  2026-04-29

  This thought-leadership article explores the mechanistic underpinnings and translational strategies for deploying EZ Cap™ Cre mRNA (m1Ψ) in advanced gene editing applications. Drawing from breakthroughs in extrahepatic mRNA delivery and mRNA stabilization, it guides researchers through practical protocol parameters, competitive innovation, and the future of programmable mRNA therapeutics.

• G007-LK Tankyrase 1/2 Inhibitor: Precision Tools for Wnt & A

  2026-04-29

  G007-LK enables reliable Wnt/β-catenin pathway inhibition and β-catenin degradation, transforming APC mutation colorectal cancer and Hippo pathway studies. Unlock actionable protocols, troubleshooting wisdom, and cross-pathway insights with APExBIO’s validated tankyrase 1/2 inhibitor.

• Topotecan HCl: Applied Topoisomerase 1 Inhibitor Workflows

  2026-04-28

  Topotecan HCl is a potent topoisomerase 1 inhibitor that enables precise induction of DNA damage and apoptosis in diverse cancer models. This guide offers actionable protocols, troubleshooting strategies, and advanced workflow integrations, positioning APExBIO’s Topotecan HCl as an essential tool for translational oncology and DNA damage research.

• BMS-345541 Hydrochloride: Precision IKK Inhibitor for Advanc

  2026-04-28

  BMS-345541 hydrochloride empowers researchers to precisely dissect NF-κB signaling with high selectivity, supporting breakthrough discoveries in inflammation and cancer biology. Its robust solubility and proven in vitro and in vivo efficacy make it the gold-standard IKK inhibitor for translational studies and protocol optimization.

• SB 202190: p38 MAP Kinase Inhibitor for Neuroinflammation Mo

  2026-04-27

  SB 202190 empowers precise modulation of the p38 MAPK pathway in cellular and animal models, enabling detailed investigation of neuroinflammatory mechanisms. This guide translates recent experimental breakthroughs—such as astrocyte-driven microglial polarization—into actionable workflows for inflammation and cancer therapeutics research.

• Fludarabine: DNA Synthesis Inhibitor for Oncology Research

  2026-04-27

  Fludarabine is a purine analog DNA synthesis inhibitor with validated apoptosis-inducing activity in leukemia and multiple myeloma research. It disrupts DNA replication, leading to cell cycle arrest and robust caspase activation. Benchmark assays confirm its nanomolar potency and mechanistic specificity.

• Lymphodepleting Chemotherapy Enhances T Cell Therapy via Ant

  2026-04-26

  Sagie et al. report that lymphodepleting chemotherapy remodels the tumor antigenic landscape, increasing immunoproteasome activity and HLA-I expression to improve neoantigen presentation. This synergistically augments the efficacy of neoantigen-directed T cell therapies, offering new mechanistic insights for optimizing adoptive cell therapy regimens.

• Cefiderocol and Ceftolozane: In Vitro Efficacy Against Resis

  2026-04-25

  This article evaluates the landmark multicenter study assessing cefiderocol’s in vitro activity against European Pseudomonas aeruginosa and Acinetobacter spp., including multidrug-resistant isolates. The findings underscore cefiderocol’s high susceptibility rates, benchmarked against β-lactam/β-lactamase inhibitor combinations such as ceftolozane-tazobactam, and offer critical context for researchers developing antibacterial susceptibility assays.

• EZ Cap™ Human PTEN mRNA: Transforming Tumor Suppressor Resto

  2026-04-24

  EZ Cap™ Human PTEN mRNA empowers researchers with ultra-stable, highly translatable tumor suppressor gene mRNA for advanced cancer and gene therapy research. This guide delivers actionable protocols, real-world troubleshooting, and insights from pioneering transdermal delivery studies to maximize experimental success.

• iPSC Airway Models for Cystic Fibrosis Drug Testing: A Multi

  2026-04-24

  This article examines a Nature Communications study that establishes a multimodal induced pluripotent stem cell (iPSC) platform for evaluating cystic fibrosis (CF) therapies. The platform's ability to represent diverse CFTR genetic variants and its integration of advanced functional assays mark important advances for personalized and translational CF research.

• iRhom2 Regulates Olfactory Receptor Adaptation in Sensory Ne

  2026-04-23

  This study demonstrates that iRhom2 is uniquely expressed in olfactory sensory neurons and governs the activity-dependent adaptation of odorant receptor gene expression. The findings reveal a mechanistic feedback loop involving odor stimulation, iRhom2/ADAM17 signaling, and transcriptional changes, with implications for understanding olfactory plasticity and receptor regulation.

• PD 173074: Precision FGFR Inhibition for Cancer Research

  2026-04-23

  PD 173074 delivers unmatched selectivity and potency for dissecting the FGFR and VEGFR2 signaling pathways in cancer and angiogenesis models. This article details optimized workflows, practical troubleshooting, and evidence-based insights to help researchers maximize the translational impact of PD-173074 in both in vitro and in vivo studies.

• D-Luciferin Sodium Salt: Precision Firefly Luciferase Substr

  2026-04-22

  D-Luciferin sodium salt empowers sensitive ATP-dependent bioluminescence assays, transforming workflows in live-cell imaging and oncology research. This article bridges innovative CAR macrophage programming with hands-on troubleshooting tips, leveraging APExBIO’s reagent for next-generation metabolic assessment.

15812 records 1/1055 page Next 12345 下5页 Last page